Please ensure Javascript is enabled for purposes of website accessibility

3 Cancer Treatment Stocks to Buy Right Now

By David Haen - Updated Mar 19, 2020 at 8:45AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cancer is one of the most competitive -- and lucrative -- areas for biotech investors.

For those with cash on the sidelines, the precipitous market drop means there are currently some promising companies at attractive prices. Let's delve into three exciting cancer drug developers worth strong consideration.

One has successfully commercialized its cancer drug and is expanding its pipeline. Another just received accelerated approval from the U.S. Food and Drug Administration (FDA) for its promising new cancer drug. And the third awaits with bated breath the FDA's approval decision for its lead cancer drug. 

A target hovers over a spreading cancer cell.

Image source: Getty Images.

1. Exelixis

I have trouble understanding how Exelixis (EXEL -3.55%) remains independent. This profitable cancer drug manufacturer posted $967.8 million in full-year revenue for 2019. That translated into earnings per share (EPS) of $1.02 on a GAAP basis, or $1.16 on a non-GAAP basis. 

Exelixis plans to spend $460 million to $500 million on R&D in 2020 to fund six ongoing trials, including three additional pivotal trials using the cancer drug cabozantinib and up to three new investigational drug filings. Positive news from any of these trials should push the stock price higher.

Exelixis' recent $4.4 billion valuation seems remarkably cheap for this quality biotech. The company had $1.4 billion in cash on its balance sheet as of Dec. 31. For 2020, revenue guidance comes in at $850 million to $900 million, with approximately 85% coming from product sales. The remainder comes from partnering pacts. If you strip out the cash from the valuation, the stock is trading at just higher than 3 times sales.

Currently in the mid-$14 range, Exelixis' stock has plenty of room to grow. The bigger question is whether Exelixis will remain independent or be acquired for its profitable cancer drugs.

2. Epizyme

2020 will be a defining year for Epizyme (EPZM -0.34%). Its drug Tazverik, an inhibitor of the cancer-promoting enzyme EZH2, earned accelerated approval from the FDA on Jan. 23 as a treatment for patients with a soft tissue cancer called epithelioid sarcoma who were ineligible for surgery. Now, the company is tasked with pulling off a successful drug launch.

Tazverik could potentially garner a second approval, this time for follicular lymphoma. The FDA granted a PDUFA date of June 18 to complete its "priority review" of the program, though amidst the backdrop of the current COVID-19 outbreak, this and other deadlines may be affected.

Based on recent Securities and Exchange Commission (SEC) filings by institutional investors, the smart-money crowd was clamoring to own the stock. More than 91% of the stock was in institutional hands, according to those filings. The company also boasts partnerships with GlaxoSmithKline, Bristol Myers Squibb, and Japanese pharma Eisai

3. Immunomedics

Immunomedics (IMMU) looks attractive at its current valuation. Having traded in the $18 to $20 range, the stock lost about 50% in the recent sell-off to a price of about $10 today.

Immunomedics seeks approval of its antibody-drug conjugate (ADC), sacituzumab govitecan, as a treatment for metastatic triple-negative breast cancer. The FDA now holds a revised application for approval and has issued Immunomedics a PDUFA target action date of June 2.

ADCs are molecules that use a cancer-targeting antibody to deliver potent cancer-fighting toxins, and they have broad applicability. Immunomedics expects its confirmatory phase 3 clinical trial to produce results around mid-year. Meanwhile, enrollment continues for trials in urothelial cancer and metastatic non-small cell lung cancer.

The lion's share of R&D at Immunomedics focuses on sacituzumab govitecan. If the FDA grants approval, I believe this company will be acquired. Buy shares now to take advantage of the discount.

There you have it. Three arguably discounted cancer treatment stocks that biotech investors should consider for their portfolios. Exelixis, the profitable 25-year-old biotech with nearly $1 billion in sales is the conservative play in this group. The stocks of Epizyme and Immunomedics, while riskier, have greater upside potential if the companies can secure FDA approvals and successfully launch their respective cancer drugs. These prices likely will not last, so grab shares while you can. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exelixis, Inc. Stock Quote
Exelixis, Inc.
EXEL
$21.48 (-3.55%) $0.79
Immunomedics, Inc. Stock Quote
Immunomedics, Inc.
IMMU
Epizyme Stock Quote
Epizyme
EPZM
$1.48 (-0.34%) $0.01
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$76.35 (0.51%) $0.39
GSK Stock Quote
GSK
GSK
$42.99 (-0.72%) $0.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.